Loading
Life sciences · Journal article
Frontiers in Pharmacology · September 25, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
The tumor microenvironment is a complex ecosystem where the extracellular matrix serves as a dynamic signaling hub and regulates tumorigenesis. Thrombospondin-2 (THBS2), a matricellular extracellular matrix protein, has traditionally been regarded as an inhibitor of angiogenesis. However, emerging evidence reveals a pleiotropic and paradoxical pro-tumorigenic role of THBS2 in several malignancies. THBS2 has been identified as a multifaceted regulator of critical mechanisms driving cancer progression including angiogenesis induction, vasculogenic mimicry, sustained proliferation, invasion, metastasis, phenotypic plasticity, and immune suppression in aggressive cancers. By modulating diverse signaling pathways, especially the PI3K/AKT/mTOR axis, remodeling the collagenous architecture of the extracellular matrix, and formation of non-endothelial vascular channels, THBS2 supports tumor progression and metastasis. This minireview encompasses current research regarding the emerging molecular mechanisms by which THBS2 regulates pro-tumorigenic functions and discusses its role in resistance to therapy. The diagnostic and prognostic value of THBS2, particularly in aggressive cancers, underscores the need for the development of novel therapeutics specifically targeting this deregulated protein.